https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.ophthalmologymanagement.com/media/pj0b5iux/1025-omd-cover-image.png
Ophthalmology Management
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.ophthalmologymanagement.com/media/43vf3gam/cover_oct25_web.jpg
Retinal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.ophthalmologymanagement.com/media/0s0ksauu/0925-gp-cover.jpg
Glaucoma Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.ophthalmologymanagement.com/media/0jsmmz3o/op_1025_cover_final.jpg
Ophthalmic Professional
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.ophthalmologymanagement.com/media/jdnlmuh3/1025-oasc-cover-final.jpg
The Ophthalmic ASC
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.ophthalmologymanagement.com/media/aqbjxwjw/pp-cover.jpg
Presbyopia Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.ophthalmologymanagement.com/media/npjdtl1w/cp_november_cover.jpg
Corneal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.ophthalmologymanagement.com/media/mvqdq2hc/nrp_cover_october_2024.jpg
New Retinal Physician
Wednesday, October 22, 2025
REMAIN results showed sustained, 3-line vision gains vs baseline through 152 weeks for MCO-010 in patients having severe vision loss from retinitis pigmentosa, and a favorable safety profile
Monday, October 20, 2025
Data provide insights that informed the phase 1 study of STK-002 as a potential disease-modifying medicine for ADOA, including disease etiology, progression, and clinical assessments.
Monday, October 20, 2025
Metis HU expands the company's Metis 900 ophthalmic microscope system with an integrated digital 3D visualization platform
Monday, October 20, 2025
The keratoconus treatment offers an incision-free alternative to traditional corneal cross-linking procedures.
Monday, October 20, 2025
In the GATHER2 open-label extension study, Izervay reduced GA growth 37-40.5% vs projected sham, with earlier intervention resulting in greater protection of retinal tissue area, the company said.
Monday, October 20, 2025
Data supports advancing high-dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal phase 3 trial in H1 2026, the company said.
Monday, October 20, 2025
Big data study offers possible new insights into a longstanding question
Monday, October 20, 2025
Studies presented this week at the annual meeting of the American Academy of Ophthalmology offer mixed results on the popular weight loss drugs and eye health.
Monday, October 20, 2025
New research challenges findings about AREDS supplements for patients with geographic atrophy.
Sunday, October 19, 2025
The study demonstrates that patients can undergo successful surgery with minimal oral sedation instead of with intravenous sedation at hospitals or ASCs.
Sunday, October 19, 2025
New study shows machine learning algorithm significantly outperformed human graders at diagnosing glaucoma.
Sunday, October 19, 2025
A study shows ophthalmologists can cut costs by two-thirds without compromising patient care.
Friday, October 17, 2025
The latest updates include additional language support, new Ocular Motility and Cover Testing modules, and multiexam integration.
Friday, October 17, 2025
The company's digital SLT+YAG platform now features advanced HD imaging and seamless connectivity, among other features.
Friday, October 17, 2025
Pickleball-playing ophthalmology resident raises awareness on the importance of protective eyewear for all players.
Friday, October 17, 2025
New study reveals a sharp increase in devastating vision loss after the state legalized consumer fireworks in 2017.
Friday, October 17, 2025
American Academy of Ophthalmology’s IRIS Registry powers 22 new clinical studies
Thursday, October 16, 2025
As part of the annual observance from Prevent Blindness, the organization will offer free inflammatory eye disease educational resources to the public and professionals.
Thursday, October 16, 2025
Nordic Pharma, Inc. will feature Lacrifill Canalicular Gel, as well as recently published Lacrifill patient data and patient experience study results with attendees at AAO.
Thursday, October 16, 2025
The AI-powered device offers 11 ocular testing modalities.
Thursday, October 16, 2025
The device combines 200° single-shot true-to-life color imaging with advanced swept-source optical coherence tomography.
Tuesday, October 14, 2025
KB801 is a redosable eyedrop gene therapy designed to enable sustained, localized expression and secretion of nerve growth factor by epithelial cells in the front of the eye for the treatment of neurotrophic keratitis.
Tuesday, October 14, 2025
According to the company, AlloFlo Uveo is a first-of-its-kind surgical treatment targeting the uveoscleral pathway.
Tuesday, October 14, 2025
The third-generation Finevision HP incorporates BVI’s proprietary POD platform and CoPODize technology, harmonizing light distribution and minimizing visual disturbances.
Monday, October 13, 2025
The company's EpiSmart Epithelium-On Cross-Linking System is designed for the simultaneous bilateral treatment of keratoconus across a wide range of severity.
Monday, October 13, 2025
The webinar for eyecare professionals will highlight the critical role of mental health support in treating patients with retinal degenerative diseases.
Monday, October 13, 2025
The company formerly known as EyeQ Technologies will unveil new surgical and diagnostic tools at the AAO meeting this week in Orlando.
Monday, October 13, 2025
The aflibercept biosimilar is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.
Monday, October 13, 2025
The approval follows the successful completion of a pivotal Investigational Device Exemption study.
Thursday, October 9, 2025
The partnership expands federal access to DefEYE’s portfolio of ophthalmic-biologic products, improving eye care for veterans and military patients.
Thursday, October 9, 2025
By including an exclusively East Asian population, RESTORE-1 strengthens the clinical evidence supporting IGF-1R inhibition for the treatment of thyroid eye disease and broadens its potential application to diverse ethnic groups.
Wednesday, October 8, 2025
The study did not meet the primary endpoint of complete healing of persistent corneal epithelial defect at week 8 and also failed to achieve statistical significance for key secondary efficacy endpoints.
Wednesday, October 8, 2025
According to the company, the Polaris platform is the world’s first AI-supported and robotics-enabled surgical system developed specifically for ophthalmology.
Tuesday, October 7, 2025
The new platform automates and streamlines diagnostic data exchange across clinical systems.
Monday, October 6, 2025
The study will evaluate safety and visual outcomes of the SING IMT device in late-stage AMD patients with prior cataract surgery. A US trial of the telescope is also underway.
Monday, October 6, 2025
According to Regenxbio, topline data is expected in late 2026 as ABBV-RGX-314 advances toward regulatory submission for wet AMD.
Monday, October 6, 2025
The updated formulation is available through optometric and ophthalmic offices, retail pharmacies, and online retailers.
Monday, October 6, 2025
People with vision loss, their families, caregivers, and researchers will share a wide range of experiences during Blindness Awareness Month
Monday, October 6, 2025
NCX 470 maintained robust IOP reduction during the 6-12 month period with no additional safety signals seen.
Friday, October 3, 2025
Coinciding with the 2025 American Academy of Ophthalmology Annual Meeting, the company debuts expanded services and tools for real-world insights from 85 million+ de-identified patients
Thursday, October 2, 2025
Privosegtor ACUITY trial showed improved LCVA and preservation of ganglion cells in acute optic neuritis.
Wednesday, October 1, 2025
DefEYE has exclusive commercial rights to the Biovance franchise of products including Biovance 3L Ocular and Biovance amniotic decellularized basement membrane products.
Tuesday, September 30, 2025
Professional product sample distribution has been initiated nationwide, and commercial product shipments will be initiated to consumers in October through the company's ePharmacy partner.
Tuesday, September 30, 2025
Pediatric patients treated with OPGx-LCA5 gene therapy show early improvements in vision and retinal sensitivity.
Monday, September 29, 2025
Neurotech’s implant, the first FDA-approved treatment for MacTel, will have streamlined billing and reimbursement beginning October 1.
Monday, September 29, 2025
The new code, Q5155, supports reimbursement for Yesafili (aflibercept-jbvf, Biocon Biologics) for nAMD, macular edema following RVO, DME, and diabetic retinopathy.
Friday, September 26, 2025
Beginning in late 2025 and expanding into 2027, HAFA will provide a single, unified access point for prescribers and patients, offering affordability, streamlined prescribing, and predictable access, Harrow said.
Friday, September 26, 2025
The acquisition centers on MELT-300, a sublingual sedation candidate.
Thursday, September 25, 2025
Authorization expands treatment choices for children with nearsightedness
Thursday, September 25, 2025
The product is the generic equivalent of Lumigan (bimatoprost ophthalmic solution) 0.01%, whose design is a trademark of Allergan, Inc., an AbbVie company, Amneal Pharmaceuticals said in a press release.
Tuesday, September 23, 2025
Building on positive results from the phase 2 proof-of-concept trial of urcosimod, the company will advance to a multiple-ascending-dose clinical trial with approximately 100 neuropathic corneal pain patients across several US clinical sites.
Tuesday, September 23, 2025
FDA grants Priority Review to idebenone for Leber hereditary optic neuropathy (LHON), with an action date of February 28, 2026
Tuesday, September 23, 2025
Part B of the ongoing multicenter clinical trial is evaluating a total of 9 adults and 3 pediatric patients with XLRS.
Monday, September 22, 2025
The IOP-lowering topical therapy represents the company’s first offering in ophthalmology.
Friday, September 19, 2025
The multimodal platform, powered by robotic intelligence, is designed to enable delegated testing, deliver data-driven insights, and enhance patient engagement, according to Topcon.
Thursday, September 18, 2025
Both wet and dry forms of AMD were elevated in psoriasis patients, though associations appeared stronger for the wet form.
Tuesday, September 16, 2025
Data demonstrates that the Unity VCS streamlined platform and integrated controls result in measurable time savings in the overall workflow, compared to earlier platforms.
Tuesday, September 16, 2025
Prevent Blindness announced a series of events and initiatives leading up to World Sight Day on Oct. 9, aligning with the organization that leads the global observance, International Agency for the Prevention of Blindness.
Monday, September 15, 2025
Joint effort focuses on making VR eye care solutions accessible to more providers and patients
Monday, September 15, 2025
The recently initiated phase 1b/2 study of TH103 is intended to inform dose selection for a potential phase 3 development program, with initial data expected next year.
Monday, September 15, 2025
A multicenter, real-world study presented at ESCRS shows the TECNIS PureSee EDOF provided excellent distance, very good intermediate, and functional near vision, with minimal refractive error.
Monday, September 15, 2025
Study shows that AI algorithm was able to predict disease progression from images taken at the first visit alone, with data from a second visit improving accuracy to 90%.
Monday, September 15, 2025
Study findings presented at ESCRS reveal that 58% of the general population experiences dry eye symptoms, but only 20% of Europeans and 17% of Americans with symptoms were formally diagnosed.
Monday, September 15, 2025
Eye drops containing pilocarpine and diclofenac could reduce dependence on reading glasses for patients with presbyopia, according to new data presented at European Society of Cataract and Refractive Surgeons (ESCRS).
Monday, September 15, 2025
Two major studies presented at the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Copenhagen
Monday, September 15, 2025
This software leverages ultra high-resolution images of the cornea’s microstructure, all captured in a single, rapid scan.
Monday, September 15, 2025
With the development of asymmetrically laser-cut segments, surgeons can tailor ring sizes and geometries to match irregular corneal topographies and unique patient anatomy, according to LWVI.
Friday, September 12, 2025
The Elara 900 slit lamp and the Refractor 900 digital phoropter will both make their international debut at ESCRS 2025 in Copenhagen, Denmark, and their US debut at the AAO 2025 in Orlando.
Friday, September 12, 2025
Senseye technology uses AI and computer vision to analyze ocular metrics such as pupil dynamics and eye movement, captured via a smartphone camera.
Friday, September 12, 2025
Data from a phase 1/2 trial of the oral agent show significant slowing of ellipsoid zone loss over 2 years.
Friday, September 12, 2025
Inflammasome Therapeutics reports that K8 slowed the rate of lesion growth by more than 50% at 3 months in an early trial.
Thursday, September 11, 2025
SAR402663 is a one-time intravitreal treatment that could reduce injection burden for patients.
Wednesday, September 10, 2025
Asana lenses maintain shape throughout the day, resist protein buildup, and provide enhanced visual acuity, particularly for patients with complex vision challenges such as astigmatism, keratoconus and post-surgical conditions.
Wednesday, September 10, 2025
OOSS urges members to contact CMS with objections by September 15.
Tuesday, September 9, 2025
According to Alcon, Wavelight Plus considers each patient’s unique optical system, including the cornea, anterior chamber, and crystalline lens.
Tuesday, September 9, 2025
The policy change, which begins October 1, means greater access to innovative glaucoma treatments.
Tuesday, September 9, 2025
In data presented at Euretina 2025, more than half of Asian patients with polypoidal choroidal vasculopathy required fewer injections after a year of Vabysmo therapy.
Tuesday, September 9, 2025
Following implantation of the CorNeat KPro, the patient regained perfect vision (6/6 or 20/20) and remains stable 11 months post-operation.
Friday, September 5, 2025
The requirement will apply to 5 services in 10 states.
Friday, September 5, 2025
Updated phase 1/2 data presented at Euretina suggest AAVantgarde's AAVB-081 may improve measures of vision.
Friday, September 5, 2025
Data presented at the EURetina congress in Paris highlight transferrin’s potential role in dry AMD progression.
Friday, September 5, 2025
Data on patients with DME, reported at Euretina, show BCVA gains and improvement in retinal thickness at 12 weeks.
Friday, September 5, 2025
Patients with diabetic macular edema who received the Iluvien implant needed less than half as many injections as those treated with aflibercept alone.
Friday, September 5, 2025
European retina experts call for multimodal imaging, early specialist referral, and strategies that address the broader impact of geographic atrophy on patients’ quality of life.
Friday, September 5, 2025
Phase 2 results presented at Euretina showed reduced injection frequency as well as improvements in retinal structure and visual function.
Thursday, September 4, 2025
The pivotal phase 3 trial will evaluate phentolamine ophthalmic solution 0.75% as a treatment for keratorefractive patients with significant chronic night driving impairment.
Thursday, September 4, 2025
The FDA-approved Valeda system adds noninvasive dry AMD therapy to Alcon’s retina portfolio.
Thursday, September 4, 2025
Throughout September, eyecare professionals can access programs and resources designed to guide practitioners at every step of building effective myopia management programs.
Wednesday, September 3, 2025
The technology lets patients "try on" intraocular lens options in immersive 3D environments before surgery.
Tuesday, September 2, 2025
According to the company, the flagging system is precise and enables fast, targeted searches across historical records and large datasets—including OCT scans from different devices.
Tuesday, September 2, 2025
The Ahmed ClearPath ST features a smaller tube lumen, a prethreaded 6-0 Prolene ripcord suture, and a 25-gauge needle for the scleral tunneling.
Tuesday, September 2, 2025
The agency has requested additional evidence of efficacy for Outlook’s ophthalmic bevacizumab formulation for wet AMD.
Tuesday, September 2, 2025
As part of a newly announced clinical project in Lusaka, Zambia, Heidelberg Engineering will deploy its Anterion advanced multi-disciplinary imaging platform.
Thursday, August 28, 2025
Retrospective cohort study of Medicare Part B claims finds substantial increase in utilization and costs of sutureless ocular amniotic membrane grafts.
By Sarah Fackler, staff writer
Thursday, August 28, 2025
According to Plexitome Medical, the device offers a more precise approach to treating recurrent corneal erosions and large cornea abrasions.
Thursday, August 28, 2025
Prevent Blindness has designated September as Sports Eye Safety Month. According to new data from the nonprofit, 43,379 sports-related eye injuries were treated in the United States in 2024, a 33% increase from 2023.
Tuesday, August 26, 2025
Next-generation subconjunctival shunts expected to drive rapid expansion through 2030.
Tuesday, August 26, 2025
The potential activity of ADX-2191 in retinitis pigmentosa is supported by results from a phase 2 clinical trial that demonstrated improvements from baseline in retinal sensitivity following treatment.
Tuesday, August 26, 2025
According to the FDA, the shift is one of many steps in the agency’s broader data modernization strategy to streamline all of its adverse event reporting systems and increase reporting frequency across all systems to identify safety signals faster.
Tuesday, August 26, 2025
The phase 2 Nightingale trial will evaluate Qlaris Bio's QLS-111 in patients with normal-tension glaucoma.
Thursday, August 21, 2025
In the phase 3 study, NCX 470 met the primary endpoint of noninferiority to latanoprost in lowering IOP.
Wednesday, August 20, 2025
The CDC notes that while indigenous Americans face higher rates of diabetes, the prevalence of diabetic retinopathy in this population has received little study.
By Sarah Fackler, staff writer
Tuesday, August 19, 2025
Opus Genetics reports that a phase 1/2 trial of its investigational gene therapy OPGx-BEST1 will begin by the end of 2025.
Monday, August 18, 2025
According to AAVantgarde Bio, AAVB-039 addresses the underlying genetic cause of the disease by providing the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations.
Monday, August 18, 2025
Recently published data from a trial terminated in 2019 showed that QPI-1007 did not meet its primary endpoint but showed potential benefit in a subgroup.
Friday, August 15, 2025
Poor sleep, low physical activity (PA), and high sedentary behavior (SB) were found to be both independently and jointly linked with an increased risk of cataract, according to a recent cross-sectional analysis, published in BMC Medicine.
Thursday, August 14, 2025
The models achieved high sensitivity and specificity across several imaging modalities for multiple IRDs, with particularly strong results for RP.
By Sarah Fackler, staff writer
Thursday, August 14, 2025
The ADAPT study will evaluate the safety and effectiveness of the company’s Calibreye Titratable Glaucoma Therapy Surgical System.
Tuesday, August 12, 2025
A Special Protocol Assessment (SPA) establishes a regulatory path for Ocular Therapeutix’s Axpaxli in diabetic eye disease.
Monday, August 11, 2025
“Findings suggest a potential temporal hierarchy in MMP activation during dry eye pathogenesis,” the researchers wrote.
Monday, August 11, 2025
The positive results from the SPECTRA trial demonstrate the tolerability and consistent, durable clinical activity of 4D-150 in DME.
Thursday, August 7, 2025
The stunning stat reveals “a profound and unprecedented shift in human behavior and health.”
Tuesday, August 5, 2025
The acquisition includes the EVO family of lenses for vision correction for patients with moderate to high myopia, with or without astigmatism.
Tuesday, August 5, 2025
Semaglutide and liraglutide showed the highest risk, while dulaglutide and exenatide were not significantly associated with NAION.
By Sarah Fackler, staff writer
Friday, August 1, 2025
Topcon aims to extend routine, AI-assisted retinal screenings to primary care practices and federally qualified health centers in addition to eyecare practices.
By Sarah Fackler, staff writer
Thursday, July 31, 2025
The study highlights the potential of AI-powered analysis of multimodal Spectralis imaging to accelerate genetic diagnosis in patients with inherited retinal diseases.
Thursday, July 31, 2025
Near vision improvements were demonstrated within 30 minutes and lasted up to 10 hours in clinical trials.
Thursday, July 31, 2025
Optomed Lumo offers programmable workflows, intuitive user guidance and seamless integration into various medical workflows, the company says.
Thursday, July 31, 2025
Optomed Lumo offers programmable workflows, intuitive user guidance and seamless integration into various medical workflows, the company says.
Tuesday, July 29, 2025
Tryptyr (acoltremon ophthalmic solution) 0.003% is now available to prescribe to patients.
Tuesday, July 29, 2025
According to Sight Sciences, all mean signs and symptoms remained statistically significantly better than the study baseline at all timepoints measured through the end of the study at 24 months.
Tuesday, July 29, 2025
The study met its primary objective, confirming that Lumify Preservative Free is statistically non-inferior to Lumify in reducing ocular redness in adults.
Tuesday, July 29, 2025
Prevent Blindness is offering free resources on children’s vision topics, including eye conditions, safety, eye patching and more.
Tuesday, July 29, 2025
More than 400 patients have been enrolled and randomized in the pivotal phase 3 trial of Duravyu for treatment of wet age-related macular degeneration.
Monday, July 28, 2025
Friday, July 25, 2025
Topline pivotal phase 3 data is expected in the second half of 2026.
Friday, July 25, 2025
The Galilei CTAK module is now available in the US market.
Thursday, July 24, 2025
A coalition of leading eye care and research organizations has launched a nationwide campaign to protect the National Eye Institute (NEI) from proposed federal restructuring and funding cuts.
Wednesday, July 23, 2025
The collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis.
Tuesday, July 22, 2025
Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile, the company reported.
Tuesday, July 22, 2025
The study did not meet its primary endpoint of complete resolution of debris after 6 weeks of twice-daily dosing.
Friday, July 18, 2025
The study results indicate that the topical application of CMPs could have a therapeutic effect on ocular diseases in which reduced tissue stiffness and integrity caused by ocular stress is a factor, including myopia.
Friday, July 18, 2025
The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2025.
Friday, July 18, 2025
The introduction of Altris Sync for automated upload of OCT files is designed to remove the need for manual operations and bring AI decision support for OCT analysis to every clinic.
Thursday, July 17, 2025
The study found that 74% of adverse drug reactions were non-serious.
Thursday, July 17, 2025
Harrow to assume full commercial responsibility for Byooviz and Opuviz by the end of 2025
Wednesday, July 16, 2025
The rule would raise ASC payment rates by 2.4%.
Wednesday, July 16, 2025
After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain.
Wednesday, July 16, 2025
The FDA-cleared Scanly home OCT device shows comparable performance to standard clinic OCT.
Wednesday, July 16, 2025
The company prepares for early trials as SAR446597 receives FDA fast track designation.
Tuesday, July 15, 2025
Ford Medical will distribute Aeye's AI screening solutions, enabling pharmacies and non-acute centers to offer an in-house, non-invasive eye exam that delivers immediate diagnostic results.
Tuesday, July 15, 2025
The report reveals divergent growth trajectories between developing and developed regions and highlights shifting trends in global glaucoma drug usage.
Tuesday, July 15, 2025
CELESTE will evaluate a dual-vector treatment designed to restore the full-length ABCA4 protein in Stargardt patients.
Tuesday, July 15, 2025
Phase 2b data support one-time, office-based MCO-010 injection for retinitis pigmentosa.
Friday, July 11, 2025
The RainDrop Dispenser Aid is a newly refined device designed to help Americans who have dry eye apply mono-dose eyedrop vials more easily and accurately.
Thursday, July 10, 2025
This expansion builds on favorable efficacy and safety data from Part A of the LIGHTHOUSE study.
Tuesday, July 8, 2025
Twelve-month topline data from this trial are expected in the second half of 2026.
Tuesday, July 8, 2025
The International Myopia Institute (IMI) announced the publication of its latest consensus editorial “Myopia Correction, Myopia Control, and Myopia Management: Definitions and Recommended Usage.”
Monday, July 7, 2025
Preliminary results from the study are anticipated early 2026, subject to patient recruitment.
Monday, July 7, 2025
The company has added more than 100 products to its suture and needle portfolio.
Monday, July 7, 2025
Alcon and LumiThera anticipate the acquisition to be completed in the third quarter of 2025.
Wednesday, July 2, 2025
After a comprehensive review, the company identified a potential concern and introduced an enhanced bottle design featuring advanced backflow prevention technology to help protect against microbial contamination.
Wednesday, July 2, 2025
The ophthalmic gel is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery.
Wednesday, July 2, 2025
Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet AMD.
Tuesday, July 1, 2025
88% of survey respondents who are currently using prescription treatments said they wish they had started sooner.
By Sarah Fackler, staff writer
Thursday, June 26, 2025
The VEGA-3 trial met its primary endpoint, with a statistically significant 27.2% of participants treated with phentolamine ophthalmic solution 0.75% achieving a ≥15-letter improvement in binocular DCNVA, with less than a 5-letter loss in binocular BCDVA at 12 hours post-dose on Day 8, compared to 11.5% of patients on placebo (P<.001).
Wednesday, June 25, 2025
Prevent Blindness is once again declaring July as Dry Eye Month with the goal to raise awareness and educate the public and health care professionals on dry eye.
Wednesday, June 25, 2025
The Vision Council (TVC) Foundation has officially launched its 2025 National Sunglasses Day campaign, set for June 27, with a lineup of new initiatives, event details, and industry partnerships aimed at raising awareness about the importance of UV-protective eyewear.
Wednesday, June 25, 2025
The contact lens provides patients crisp, clear, stable vision at all distances and in all lighting conditions.
Tuesday, June 24, 2025
Results highlight ST-100's potential for fast-acting healing of ocular surface damage caused by dry eye disease.
Monday, June 23, 2025
The Waiva is designed to address daily exposure to makeup, screens, medications, and environmental stressors that lead to the buildup of debris, oils, and eyelash mites around the eyes.
Monday, June 23, 2025
The testimony urged US Senate subcommittee to deliver strong, sustained funding for the NEI and maintain the NEI’s status as an independent NIH institute in the FY2026 appropriations cycle.
By Sarah Fackler, staff writer
Friday, June 20, 2025
New review provides an overview of classification, diagnostics, and treatments
By Sarah Fackler, staff writer
Thursday, June 19, 2025
Nearly 40% of patients on combined therapy achieved zero axial elongation over 12 months.
By Sarah Fackler, staff writer
Wednesday, June 18, 2025
The survey findings showed a majority of participants had a favorable experience injecting Acthar Gel via SelfJect, with a high level of satisfaction, confidence, convenience, and ease of use regarding the injector,¹ the company said.
Tuesday, June 17, 2025
Per FDA agreement, the only new clinical data included in the resubmitted new drug application were from the recently completed dry eye chamber trial, which achieved the primary endpoint, according to the company.
Tuesday, June 17, 2025
The phase 2/3 clinical trial for OCU410ST, a modifier gene therapy candidate, will enroll 51 participants diagnosed with Stargardt disease. The primary objective of the trial is to evaluate the reduction in atrophic lesion size.
Tuesday, June 17, 2025
Researchers find systolic blood pressure and heart rate are correlated with IOP, though more studies into the specific mechanism are needed.
By Sarah Fackler, staff writer
Monday, June 16, 2025
The Fair Financing Principles establish a new standard for transparency and education for financing options, Synchrony said in a press release.
Friday, June 13, 2025
Prednisolone acetate ophthalmic suspension, USP 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is indicated for treating steroid-responsive ocular inflammation.
Thursday, June 12, 2025
Further studies are needed to bolster certainty, but confirmation could save injections in insufficient responders.
By Sarah Fackler, staff writer
Monday, June 9, 2025
Harrow said it expects Byqlovi (clobetasol propionate ophthalmic suspension) 0.05% to be available in the fourth quarter of 2025.
Friday, June 6, 2025
Primarily intended for pediatric use, HVS-1 performs rapid vision screening for infants and toddlers in less than a second with high accuracy, the company said.
Friday, June 6, 2025
Researchers explore similarities in one peptide motif between central nervous system autoimmunity and noninfectious ocular inflammation.
By Sarah Fackler, staff writer
Thursday, June 5, 2025
VeonGen announces new name and progress in its VG801 clinical program, which targets genetic mutations linked to Stargardt disease.
Thursday, June 5, 2025
Both products are preservative-free, contact-lens friendly and formulated to provide hydration and comfort for dry eyes in a multi-dose bottle, according to the company.
Tuesday, June 3, 2025
The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026, for Brimochol PF.
Monday, June 2, 2025
The phase 3 study of Axpaxli in wet AMD reaches its randomization target of 555 patients ahead of schedule.
Monday, June 2, 2025
Phentolamine Ophthalmic Solution 0.75% met its phase 3 primary endpoint of ≥ 15-letter (≥ 3-line) gain in mesopic low-contrast distance visual acuity in comparison to placebo.
Monday, June 2, 2025
Researchers discuss associations with axial length, eye shape, staphylomas, and more.
By Sarah Fackler, staff writer
Friday, May 30, 2025
The US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to Ocugen's OCU410ST for the treatment of ABCA4-associated retinopathy, including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.
Thursday, May 29, 2025
In pivotal phase 3 trials, Tryptyr demonstrated rapid natural tear production as early as Day 1.1-2
Wednesday, May 28, 2025
Prevent Blindness is offering free cataract resources including fact sheets, social media graphics, a dedicated web page, expert video and a listing of financial assistance for eye care.
Wednesday, May 28, 2025
These cytokines have also been implicated in DR, AMD, uveitis, and other ocular diseases.
By Sarah Fackler, staff writer
Tuesday, May 27, 2025
EyePoint Pharmaceuticals has enrolled and randomized more than 400 patients in the phase 3 LUGANO pivotal trial of Duravyu for the treatment of wet age-related macular degeneration (wet AMD), exceeding its enrollment target.
Tuesday, May 27, 2025
A favorable safety profile plus significant ocular surface healing for ILYX-002 support advancement to phase 3, the company said.
Friday, May 23, 2025
Investigators at the National Institutes of Health engineered a surgical clamp that stabilizes intraocular pressure during the sequential implantation of 2 tissue patches while minimizing trauma to surrounding tissue.
By Sarah Fackler, staff writer
Friday, May 23, 2025
Prevalence of refractive astigmatism increased more than 10% between 2019 and 2023, while prevalence of corneal astigmatism increased 6%.
By Sarah Fackler, staff writer
Thursday, May 22, 2025
This is the third approved indication for the ranibizumab injection, which is delivered via the refillable port delivery system.
Thursday, May 22, 2025
Lumify Preservative Free redness reliever eye drops are the first and only preservative-free over-the-counter eye drops with low-dose brimonidine tartrate 0.025% that relieve redness of the eye due to minor eye irritations, Bausch + Lomb said.
Wednesday, May 21, 2025
An IG eye drop is an anti-inflammatory and immunomodulatory biologic drug that is generated from pooled human plasma from thousands of healthy donors.
Tuesday, May 20, 2025
This novel intraocular lens (IOL) is designed to restore dynamic range of vision following cataract surgery, the company said.
Friday, May 16, 2025
Several aqueous humor parameters stimulated by nitric oxide were statistically significant or trended in favor of NCX 470.
Wednesday, May 14, 2025
A new clear tip enhances surgical visibility.
Wednesday, May 14, 2025
Pharmaceutical distributor AvKARE released an urgent voluntary drug recall notice on its website that BRS Analytical Service, LLC is initiating a voluntary recall to the consumer level for several ophthalmic products.
Tuesday, May 13, 2025
Zervimesine reduced lesion growth in patients with late-stage dry AMD by nearly 30% in a phase 2 trial.
Tuesday, May 13, 2025
Preliminary data on an investigational treatment for Leber congenital amaurosis prompts the FDA to grant the Regenerative Medicine Advanced Therapy designation.
Tuesday, May 13, 2025
The BETTER trial results support further testing of the experimental TGF-β2-blocking drug in retinal diseases, including wet AMD and DME.
Friday, May 9, 2025
The updated responder analyses highlight PL9643's rapid onset of action, broad and statistically significant efficacy, and complete symptom resolution across multiple endpoints in patients with dry eye disease.
Friday, May 9, 2025
The extension trial followed subjects that completed the pivotal LIGHTSITE III trial and resumed treatment for 13 months with the Valeda Light Delivery System.
Thursday, May 8, 2025
Data were presented from Alkeus Pharmaceuticals’ phase 2 SAGA clinical study in GA secondary to AMD.
Thursday, May 8, 2025
Anat Galor, MD, MSPH, presented data from the Oculis Phase 2b RELIEF trial that looked at the effects of licaminlimab in patients with signs of DED, and the influence of a genetic marker, the CC genotype of single nucleotide polymorphism rs1800693 in the TNFα receptor gene.
Tuesday, May 6, 2025
In a dry eye chamber trial, Reproxalap was statistically superior (P=0.002) to vehicle in primary endpoint of ocular discomfort.
Tuesday, May 6, 2025
Hint: Begin with your eye on the exits.
By Rene Luthe
Tuesday, May 6, 2025
Laru-zova was generally well-tolerated by all DAWN participants evaluated at 6 months or beyond and initial data showed promising improvements in visual function across several key measures.
Tuesday, May 6, 2025
GAL-101, an oral therapy designed to target misfolded Aβ proteins, is shown to be well tolerated in first stage of trial.
Tuesday, May 6, 2025
The VAN-2401 study will assess the safety and durability of a single-dose gene therapy for treatment of neovascular age-related macular degeneration.
Monday, May 5, 2025
The noninvasive device captures a naturally occurring fluorescence from the eye in only a few minutes per patient, according to the company.
Monday, May 5, 2025
The move accelerates the company's AI-powered imaging innovation to enable earlier interventions and better outcomes for major retinal diseases.
Thursday, May 1, 2025
"The RMAT designation is based on the review of our results to-date from our ongoing 4D-150 SPECTRA DME study, underscoring the potential of 4D-150 to sustain visual acuity improvements while dramatically reducing treatment burden for patients," said David Kirn, MD, co-founder and chief executive officer of 4DMT.
Thursday, May 1, 2025
Okyo Pharma said it remains dedicated to advancing urcosimod through clinical development and regulatory review, with a focus on addressing the significant unmet medical need in neuropathic corneal pain treatment.
Wednesday, April 30, 2025
Prevent Blindness said the goal is to educate patients on various forms of inherited retinal diseases, and the importance of genetic testing.
Wednesday, April 30, 2025
By enabling seamless integration of clinical and research data, the Zeiss Research Data Platform (RDP) empowers clinicians and scientists to accelerate discoveries through smarter, more efficient research, the company said.
Monday, April 28, 2025
A new approach could offer a potential treatment for AMD and other retinal disorders.
Monday, April 28, 2025
Study finds that protein markers in aqueous humor could help identify high-risk uveal melanomas.
Monday, April 28, 2025
According to 18-month data presented at ASCRS, cataract patients who received the lenses showed clinically meaningful IOP reduction along with improved VA.
Friday, April 25, 2025
According to Alcon, the systems feature many first-to-market technologies designed to deliver transformative surgical innovation for cataract and vitreoretinal surgery, including Unity 4D Phaco, HYPERVIT 30K and the advanced Unity Intelligent Fluidics system.
Friday, April 25, 2025
This dataset offers insights into patient demographics, clinical characteristics, and treatment pathways to support drug and treatment development.
Thursday, April 24, 2025
Maxitrol (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension), is for the treatment and relief of bacterial eye infections.
Thursday, April 24, 2025
After a thorough investigation in collaboration with a globally recognized TASS expert and an advisory group of nearly 30 top cataract surgeons including American Society of Cataract and Refractive Surgery leadership, the company determined that the issue stemmed from raw material used in certain lots that was delivered by a different vendor.
Tuesday, April 22, 2025
Previously approved for children aged 4 to 7 years, Luminopia's amblyopia treatment is now cleared for a wider patient population.
Tuesday, April 22, 2025
Patients with a family history of glaucoma were more likely to experience progression or RNFL thinning
By Sarah Fackler, staff writer
Tuesday, April 22, 2025
The noninvasive, accessible, and scalable modality can predict risk before disease endpoints can be observed.
By Sarah Fackler, staff writer
Monday, April 21, 2025
The new system features higher viscoelastic capacity and TruSync technology, engineered to safely synchronize surgical control and precision in implant-free, comprehensive MIGS, the company said.
Monday, April 21, 2025
The FDA did not agree with Regeneron’s proposal to add additional extended dosing intervals (greater than every 16 weeks, which is the maximum dosing interval currently indicated in the label).
Thursday, April 17, 2025
The agency has initiated priority review of the anti-VEGF agent as a treatment for macular edema secondary to retinal vein occlusion.
Thursday, April 17, 2025
The Laser Endoscopy Ophthalmic System is designed for early-stage glaucoma as well as a wide spectrum of glaucoma types.
Wednesday, April 16, 2025
Biocon Biologics Ltd announced a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili.
Wednesday, April 16, 2025
The safety and tolerability of ATSN-201 is currently being evaluated in the LIGHTHOUSE study in male patients ages 6 and older with a clinical diagnosis of XLRS caused by mutations in the RS1 gene.
Friday, April 11, 2025
The FDA sets an August 2025 PDUFA target to review the application of ophthalmic bevacizumab for wet AMD.
Thursday, April 10, 2025
Beginning immediately, Harrow said that more than 25,000 patients across the United States will be able to convert their Klarity-C prescriptions to Vevye (cyclosporine ophthalmic solution) 0.1% for $59 per bottle (including refills).
Thursday, April 10, 2025
The company says DIAMOND is the first and only pivotal trial program conducted with a topical treatment for diabetic macular edema.
Wednesday, April 9, 2025
In the phase 3 pivotal trial of 241 patients, tanruprubart met the primary endpoint with consistent outcomes and rapid, more complete functional recovery vs placebo across multiple time points and clinical efficacy measures.
Tuesday, April 8, 2025
Preliminary results in a pediatric patient who underwent gene therapy to treat a form of Leber congenital amaurosis show improved vision and no safety issues.
Tuesday, April 8, 2025
The NDA submission for BRIMOCHOL PF includes efficacy and safety data, and is supported by positive data from the first phase 3 BRIO-I study, which demonstrated the benefit of the combination therapy over the individual components.
Monday, April 7, 2025
According to Orasis Pharmaceuticals, Qlosi is available in single-use vials that can be taken on-the-go, and patients can fill prescriptions via 2 pharmacy partners, BlinkRx and Medvantx, and receive free home delivery.
Thursday, April 3, 2025
Unity Biotechnology reports that treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in a difficult-to-treat patient population.
Thursday, April 3, 2025
The letter identified concerns with the data from the trial submitted to the NDA that may have affected interpretation of the results, which the FDA stated may be related to methodological issues.
Wednesday, April 2, 2025
According to Alcon, PanOptix Pro has been introduced to select practices across the United States, with broad commercial availability in May. Additional markets will begin rollout in late 2025.
Monday, March 31, 2025
Currently in a phase 2b, randomized, placebo-controlled, double-masked, clinical trial to treat NCP patients, the drug showed itself stable in single-use ampoules for more than 2.5 years.
Monday, March 31, 2025
Top-line data from the Phase 3 trials of sozinibercept showed that the nAMD treatment failed to meet its primary BCVA endpoints in both studies.
Friday, March 28, 2025
Prevent Blindness offers a variety of free educational resources to help educate the public and raise awareness of women’s vision and eye health issues.
Friday, March 28, 2025
Under the terms of the agreement, the companies will work to advance the production and commercialization of Pantheon Vision’s bioengineered corneal implant.
Friday, March 28, 2025
According to the company, 90% of patients preferred the Omidria regimen compared to 42% for standard eye drops.
Thursday, March 27, 2025
As part of the transaction, Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into phase 3 for corneal edema secondary to corneal endothelial disease during the second half of 2025.
Thursday, March 27, 2025
The company said the recall is in response to an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with implantation of enVista Aspire, enVista Envy and certain enVista monofocal IOLs.
Wednesday, March 26, 2025
Through this partnership, Pentec will act as a distribution and service provider for Luminopia, offering comprehensive support services to patients and providers.
Wednesday, March 26, 2025
Maker Johnson & Johnson says nipocalimab, the first and only investigational treatment to be granted FDA Breakthrough Therapy Designation for the treatment of adults with mild to moderate Sjogren's, now has Fast Track designation as well. Currently, there are no FDA-approved advanced treatments for Sjogren’s disease.
Tuesday, March 25, 2025
According to Nanoscope, this is the first report of a gene monotherapy that can restore vision in blind patients in a mutation-independent manner utilizing an optogenetics technology platform.
Monday, March 24, 2025
The acquisition includes Ally Robotic Cataract Laser Treatment System, Lensar's proprietary Streamline software technology and Lensar legacy laser system, building Alcon’s femtosecond laser-assisted cataract surgery (FLACS) offering.
Monday, March 24, 2025
The decision, effective April 1, 2025, allows for separate reimbursement in ambulatory surgery centers (ASCs) and hospital outpatient departments (HOPDs) for 3 years.
Monday, March 24, 2025
The ophthalmic compounding company introduced products it says are designed to streamline workflows and improve patient experience.
Monday, March 24, 2025
The trial did not meet its primary endpoint of mean change in best-corrected visual acuity (BCVA) from baseline to week 52.
Friday, March 21, 2025
The companies seek to combine their drug delivery technologies in a potential $92 million transaction.
Thursday, March 20, 2025
Additionally, the company is currently enrolling nAMD patients in a phase 1 trial for its novel, differentiated anti-VEGF agent, TH103, for the treatment of neovascular and exudative diseases of the retina. Post-merger cash of approximately $100 million is expected to fund operations into the fourth quarter of 2026.
Thursday, March 20, 2025
Patients reported symptom relief in as early as 5 and 60 minutes after a single administration; and relief was maintained through the 14-day study.
Tuesday, March 18, 2025
The program ensures that every patient can affordably start treatment without delay, the company said.
Tuesday, March 18, 2025
According to Iantrek, the study confirms the long-term efficacy and safety of Iantrek’s bio-interventional platform for uveoscleral outflow enhancement in open-angle glaucoma patients undergoing combined cataract surgery.
Tuesday, March 18, 2025
These lenses include the first orthokeratology lens design with toric peripheral curves approved by the US Food and Drug Administration to treat myopia overnight, the company said.
Tuesday, March 18, 2025
The study showed that the children receiving astaxanthin reported significant improvements in eye fatigue and discomfort. The Astaxanthin group also showed improved tear production.
Tuesday, March 18, 2025
This collaboration will integrate machineMD’s objective functional neurodiagnostics with Topcon’s Harmony digital health information platform, fostering earlier detection of neurological diseases within a connected care ecosystem.
Monday, March 17, 2025
Iluvien is now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye in addition to diabetic macular edema.
Thursday, March 13, 2025
ATSN-201 leverages AAV.SPR, Atsena Therapeutics' novel spreading capsid, to achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the surgical risks of foveal detachment, the company said in a press release.
Tuesday, March 11, 2025
Together, the companies said that they aim to expand access and enable doctors to provide visual field exams and education to 100% of glaucoma patients who need this test.
Tuesday, March 11, 2025
If approved, SYD-101 would be the first and only pharmaceutical option for the treatment of progression of pediatric myopia in the United States, the company said.
Tuesday, March 11, 2025
The SSD agreement is with the current contract manufacturing organization producing Triesence, ensuring continuity in quality and leveraging more than 15 years of experience with the Triesence manufacturing process.
Monday, March 10, 2025
“It is unknown whether PE firms affect the financial incentives offered to physicians by other industry actors, which may change clinical decision-making," researchers note.
By Sarah Fackler, staff writer
Monday, March 10, 2025
Using optical coherence tomography angiography, researchers in the Journal of Imaging article observed a decrease in vessel length density in the deep capillary plexus, which suggested potential microvascular involvement in the pathogenesis of long COVID.
By Sarah Fackler, staff writer
Monday, March 10, 2025
The Preservative Freedom Coalition announced results of a new nationwide survey of the experiences of glaucoma or ocular hypertension patients, which highlight the need for dialogue between patients and their eyecare providers around preservatives.
Monday, March 10, 2025
There is currently no FDA-approved, effective treatment for neuropathic cornea pain, the company notes.
Friday, March 7, 2025
The new platform provides retina specialists with educational materials on evolving anti-VEGF treatment strategies.
Friday, March 7, 2025
The enhanced dataset will help clinicians detect and manage eye diseases at an earlier stage.
Thursday, March 6, 2025
Neurotech’s ocular insert Encelto aims to slow vision loss in patients with this degenerative retinal disease.
Thursday, March 6, 2025
The meeting and formal minutes confirmed key elements for 2 proposed phase 3, non-inferiority, pivotal trials, including agreement on the protocol design, patient population, primary and secondary endpoints, and use of sham injections.
Tuesday, March 4, 2025
The pivotal trial is designed to evaluate the efficacy and safety of the company’s Ixo-vec (ixoberogene soroparvovec) as a one-time intravitreal injection for patients with neovascular (wet) age-related macular degeneration.
Tuesday, March 4, 2025
The company said it believes that the complete data set for NORSE EIGHT and the additional CMC information in the BLA resubmission, combined with the data from the other NORSE clinical trials, provides the required evidence to support approval of the ONS-5010 BLA in the United States.
Tuesday, March 4, 2025
The new ophthalmic microscope system brings Haag-Streit’s optics into the operating room, providing sharp clarity and precision during ophthalmic surgeries.
Tuesday, March 4, 2025
Each additional hour of daily screen time was associated with a 21% increase in the odds of developing myopia, according to a new analysis.
By Sarah Fackler, staff writer
Tuesday, March 4, 2025
Signs were similar to both nonparaneoplastic autoimmune retinopathy and retinitis pigmentosa, but known etiologies differ.
By Sarah Fackler, staff writer
Tuesday, March 4, 2025
The AI-powered Advanced Optic Disc Analysis module evaluates optic disc parameters using optical coherence tomography, providing personalized assessments by accounting for individual disc sizes and angle of rim absence.
Tuesday, March 4, 2025
A poster presented at the recent American Glaucoma Society annual meeting revealed a statistically significant greater proportion of eyes treated with NCX 470 0.1% achieved mean diurnal IOPs of ≤18 mmHg compared to those in the latanoprost 0.005% group in this analysis of the multinational phase 3 Mont Blanc clinical trial.
Tuesday, March 4, 2025
The paper reports pre-specified and post-hoc analyses of angiographic predictors of response to sozinibercept combination therapy with ranibizumab in treatment-naïve patients with wet AMD.
Friday, February 28, 2025
The goal of the annual observance is to provide employers and employees with important information to help keep eyes safe and healthy at work.
Thursday, February 27, 2025
The campaign consisted of the successful production of 3 consecutive commercial-scale drug product batches required to further validate Opthea’s manufacturing process in preparation for a potential biologics license application filing and commercialization of sozinibercept in wet AMD.
Thursday, February 27, 2025
Masked analysis shows participants receiving oral zervimesine for at least 6 months experienced slower lesion growth than participants receiving placebo.
Wednesday, February 26, 2025
The company's non-selective alpha-1 and alpha-2 adrenergic antagonist is being studied for the treatment of presbyopia and the treatment of visual loss in low-light conditions associated with keratorfractive surgery.
Tuesday, February 25, 2025
The presentations will showcase new data on the clinical effectiveness and safety of OMNI across diverse patient populations.
Monday, February 24, 2025
Four children were included in this first-in-human interventional study, with a second cohort receiving sequential bilateral treatment. Legally blind at birth, all children gained visual acuity after 4 or more weeks following a single one-time delivery of rAAV8.hRKp.AIPL1.
Monday, February 24, 2025
The Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA’s review of the Epioxa NDA is set for October 20, 2025.
Monday, February 24, 2025
SYSTANE PRO PF is the longest lasting eye drop in the SYSTANE portfolio with a triple action, preservative-free formula for the temporary relief of burning and irritation due to dryness of the eye.
Friday, February 21, 2025
The Eye Health Summit, a new global patient-centered event dedicated to integrative eye health, will take place May 1-7 as a free hybrid event.
Thursday, February 20, 2025
RetinalGenix Technologies said the company has started imaging patients with its first prototype of the device using both near-infrared and green modes.
Thursday, February 20, 2025
By Jennifer Ponte Canning, Managing Editor
Wednesday, February 19, 2025
Alcon’s automated laser enables treatment without a gonio lens or manual aiming.
Tuesday, February 18, 2025
First patient dosed in the pediatric cohort of the phase 1/2 trial of OPGx-LCA5, with initial data anticipated by Q3 2025. Twelve-month data on the adult cohort to be released in the second quarter of the year.
Tuesday, February 18, 2025
The initiative, taking place Feb. 24 to March 2, supports the comprehensive “Prevent Blindness ROP Education and Support Program,” designed to provide education and support for families of children with ROP, promote the role of early intervention programs for these children and explain how allied healthcare professionals assist in continuity of care.
Tuesday, February 18, 2025
Opthea Limited completed the final week 52 patient visit in COAST, the first of two Phase 3 pivotal trials investigating the superiority and safety of sozinibercept in combination with aflibercept (COAST) or ranibizumab (ShORe), compared to standard of care alone for the treatment of wet AMD.
Tuesday, February 18, 2025
The VIA360 Surgical System delivers controlled amounts of viscoelastic fluid during ophthalmic surgeries, and is also indicated to cut trabecular meshwork tissue during trabeculotomy procedures.
Monday, February 17, 2025
The next-generation MonacoPro system integrates ultrawidefield imaging with improved diagnostic support.
Friday, February 14, 2025
American Academy of Ophthalmology provides guidance in response.
By Sarah Fackler, staff writer
Friday, February 14, 2025
Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) is a bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan Ophthalmic Solution, 0.005% of Upjohn US 2 LLC, the company said in a press release.
Thursday, February 13, 2025
The update removes limitations on treatment duration for GA secondary to AMD.
Thursday, February 13, 2025
Five-year data from the REFLECT trial of Lumevoq demonstrate long-term efficacy and safety.
Tuesday, February 11, 2025
The funding is allocated to support the clinical development of the company’s non-incisional refractive correction procedure that leverages corneal cross-linking to reshape the cornea.
Tuesday, February 11, 2025
Virtual Vision Health launched Visual Acuity testing on the Virtual Eye VR platform. The company said this addition is part of its commitment to expanding access to advanced eye care and equipping providers with a comprehensive, portable, and cloud-based diagnostic solution.
Tuesday, February 11, 2025
Applied Design, a branding and design company, joined forces with the Braille Institute to launch Atkinson Hyperlegible Next, an enhanced and expanded version of the Atkinson Hyperlegible typeface.
Tuesday, February 11, 2025
OptiLIFT, a proprietary Dynamic Muscle Stimulation technology for toning facial muscles to address lower lid laxity and impaired blinking without the need for surgery, is now available in the United States. The company expects other markets to follow.
Tuesday, February 11, 2025
3E10 vg/eye achieved an 83% reduction in injection burden vs projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection and 57% were injection-free through 52 weeks.
Monday, February 10, 2025
Results from the Phase 3 QUASAR were presented at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) 2025 annual meeting and will support the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) in the first quarter of 2025.
Monday, February 10, 2025
The autonomous slitlamp allows a staff member or remote doctor to capture images and video with the touch of a button, replicating traditional complete anterior segment evaluations while enabling reliable, repeatable results without requiring specialized training, the company said.
Thursday, February 6, 2025
Prevent Blindness provides a wealth of free educational resources on AMD, and materials on low vision, and low vision services.
Thursday, February 6, 2025
The free online course will review several topics, including: Viral delivery systems, surgical techniques, current clinical trials and endpoints, inflammation management, and future directions.
Thursday, February 6, 2025
The drug met all primary and secondary endpoints, demonstrating significant intraocular pressure (IOP) reductions and a favorable safety profile.
Thursday, February 6, 2025
Both Duravyu doses met the primary endpoint of extended time to first supplemental injection vs the aflibercept control, with the 2.7 mg dose delaying the need for additional treatment in 73% of patients.
Wednesday, February 5, 2025
The company plans to file for US regulatory approval for its novel, user-filled spray dispenser in the fourth quarter of this year.
Tuesday, February 4, 2025
Genentech’s Susvimo (ranibizumab injection) 100 mg/mL is the first continuous-delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME), the company said.
Tuesday, February 4, 2025
The device, which integrates hearing aid functionality into a pair of smart glasses, is designed to offer both vision and hearing support in a single product.
Monday, February 3, 2025
Origin matters for this hereditary ocular cancer because researchers found that male and female copies of the mutation are associated with different disease trajectories, and so would likely influence physicians' treatment recommendations.
Monday, February 3, 2025
Rayner has now closed recruitment in the Investigational Device Exemption study for the RayOne Galaxy intraocular lens in the United States.
Monday, February 3, 2025
EyeXchange Solutions connects experienced and emerging surgeons across cataract, glaucoma, and retina specialties to share insights, refine techniques, and address complex cases.
Thursday, January 30, 2025
PulseSight Therapeutics submitted a Clinical Trial Authorization to France's regulatory agency for PST-611, a first-in-class non-viral vectorized therapy for the treatment of dry age-related macular degeneration and geographic atrophy.
Thursday, January 30, 2025
Ocular Therapeutix outlined the clinical progress across its registrational program for Axpaxli in wet age-related macular degeneration (wet AMD), plans to advance Axpaxli in non-proliferative diabetic retinopathy (NPDR), and the company’s strategic outlook for 2025 in its presentation at the 43rd Annual J.P. Morgan Healthcare Conference (JPM 2025).
Thursday, January 30, 2025
According to Harrow, Harrow Cares ensures seamless enrollment, rapid access to therapy, and personalized support, enabling retina providers to confidently utilize Iheezo and Triesence in their practices.
Wednesday, January 29, 2025
The Phase 2a study is designed as a double-masked, randomized, 12-week placebo-controlled trial in neuropathic corneal pain patients. A total of 48 patients are planned to be enrolled in the trial, with NCP disease confirmed via confocal microscopy, patient symptoms and medical histories.
Tuesday, January 28, 2025
AI Optics' Sentinel Camera is a handheld retinal imaging system that captures high-quality images of the human eye.
Tuesday, January 28, 2025
Prevent Blindness received a $9.7 million donation from the Estate of Pamela Behrens, a long-time Florida resident and previous donor. The largest in Prevent Blindness's history, the donation will help support its mission to prevent blindness and preserve sight across the United States and its commitment to be a partner to organizations working to address eye health around the world.
Monday, January 27, 2025
Norlase says the battery-powered device is “the world's first and only pattern scanning laser indirect ophthalmoscope.”
Friday, January 24, 2025
Results confirmed that intravitreal ONS-5010 provided early and sustained anatomic improvements, with steady gains in BCVA and reliable, consistent safety, the company said.
Friday, January 24, 2025
The American Medical Association comments on a recent statement by US insurer UnitedHealth that it will work toward easing prior authorization rules.
Friday, January 24, 2025
The event, held at Mainz University Medical Center in Mainz, Germany, will showcase the growing role of artificial intelligence in glaucoma diagnosis and management.
Wednesday, January 22, 2025
The funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on OKYO’s lead program, OK-101, focused on treating neuropathic corneal pain.
Wednesday, January 22, 2025
The designation is for the company's AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1). It makes the fourth Rare Pediatric Disease Designation MeiraGTx has received for inherited retinal diseases.
Tuesday, January 21, 2025
Fast Track Designation represents an objective assessment by the FDA for the potential of NPI-001 tablets as a treatment for retinitis pigmentosa, the company said.
Tuesday, January 21, 2025
Short-term exposure to traffic-related air pollutants were linked with a risk of dry eye disease outpatient visits.
Tuesday, January 21, 2025
The new iCare MAIA features a renewed hardware platform with fully automated operations and a 15’’ multi-touch display, along with an intuitive user interface.
Thursday, January 16, 2025
The partnership will initially focus on AMD, with the potential to expand into other eye conditions.
Thursday, January 16, 2025
Attention private practice owners: The U.S. Small Business Administration (SBA) has opened two Business Recovery Centers (BRC) in Los Angeles County to help.
Wednesday, January 15, 2025
Five years after the one-time injection, patients with Leber hereditary optic neuropathy due to the MT-ND4 gene variant demonstrated sustained bilateral improvement in visual acuity and a favorable safety profile.
Wednesday, January 15, 2025
In a US clinical trial of five patients with bilateral geographic atrophy, sustained-release intravitreous implants of K8 were well tolerated, with no drug-related ocular or systemic serious adverse events.
Wednesday, January 15, 2025
The LIDS trial met its primary endpoint with statistical significance for the 150 mg BID dose.
Tuesday, January 14, 2025
The 3E10 vg/eye dose demonstrated notable efficacy, achieving sustained visual acuity gains.
By Jennifer Ford, content director
Tuesday, January 14, 2025
These collaborations establish two new simulation-based surgical training locations to advance ophthalmic education while also addressing the global cataract blindness crisis.
Tuesday, January 14, 2025
Throughout January, Bausch + Lomb and Glaucoma Research Foundation will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness of the disease.
Tuesday, January 14, 2025
Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.
Tuesday, January 14, 2025
The data demonstrated that additional early-stage Stargardt disease patients treated with oral gildeuretinol acetate showed no disease progression, including stable visual acuity, over multiple years.
Tuesday, January 14, 2025
The study showed that the percentage of patients able to read at near distance increased from 28.6% at baseline to 97.1% at 6 months.
Monday, January 13, 2025
With innovative therapies addressing glaucoma and geographic atrophy currently in development, the acquisition of Whitecap Biosciences strengthens B + L’s expanding clinical-stage pipeline.
Monday, January 13, 2025
The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE and completes Corneal Refractive Workflow, company says.
Friday, January 10, 2025
Tenpoint Therapeutics' BRIMOCHOL PF successfully met the pre-specified visual acuity primary endpoints for both the United States and EU/UK with highly statistically significant near- vision improvements over 8 hours.
Thursday, January 9, 2025
The module equips eye-care professionals with advanced thickness mapping and data insights to evaluate both the epithelial and stromal structures.
Thursday, January 9, 2025
The supplemental new drug application seeks to add positive 2-year data to the IZERVAY U.S. Prescribing Information based on results from the GATHER2 Phase 3 clinical trial.
Thursday, January 9, 2025
The newly-redesigned RayTrace version 4.0 reflects surgeon feedback with quicker and clearer calculations, access to the PEARL DGS formula, and a host of other new features.
Wednesday, January 8, 2025
The research team demonstrated the effectiveness of their technique in multiple models, including human tissues.
Tuesday, January 7, 2025
Recently published results of a Phase 1 study support its potential in combination with aflibercept.
Tuesday, January 7, 2025
The strategic acquisition enables Canyon to expand its end-to-end development solutions and strengthens both organizations' market positions.
Tuesday, January 7, 2025
The acquisition will strengthen Regeneron Pharmaceuticals' gene therapy development program.
Tuesday, January 7, 2025
The acquisition aims to strengthen Cencora’s position in the specialty health-care market and expand its management services organization offerings.
Tuesday, January 7, 2025
SolidddVision’s vision correction technology can improve sight for patients with macular degeneration and other conditions.
Tuesday, January 7, 2025
EssilorLuxottica aims to leverage Espansione’s technology to advance its mission of improving vision health.
Tuesday, January 7, 2025
The Phase 2 study will examine GAL-101’s potential to slow the growth of geographic atrophy lesions.
Monday, January 6, 2025
Oculis' OCS-05 showed a favorable safety and tolerability profile compared to placebo, and achieved statistically significant results on key secondary efficacy endpoints compared to placebo, including objective structural measures of retinal thickness and visual improvement.
Friday, January 3, 2025
In an effort to support National Glaucoma Awareness Month in January, Prevent Blindness is providing patients, care partners and professionals with free educational resources.
Thursday, January 2, 2025
While the Phase 2 SPECTRA study did not meet its primary or secondary endpoints based on the analysis in the predefined primary population, certain doses tested in the study showed potential evidence of preventing disease progression.
Thursday, January 2, 2025
New year, new requirements: OOSS warns ACS that do not administer and report OHS CAHPS in 2025 could be subject to a penalty of 2% of their annual Medicare payment update.
